Alembic Revenue and Competitors
Estimated Revenue & Valuation
- Alembic's estimated annual revenue is currently $3.9M per year.
- Alembic's estimated revenue per employee is $116,000
Employee Data
- Alembic has 34 Employees.
- Alembic grew their employee count by 13% last year.
Alembic's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & Chief Creative Officer | Reveal Email/Phone |
2 | CTO/COO | Reveal Email/Phone |
3 | Head Demand Generation | Reveal Email/Phone |
4 | VP Product (Head) | Reveal Email/Phone |
5 | VP Sales and Marketing | Reveal Email/Phone |
6 | Chief Innovation Officer | Reveal Email/Phone |
7 | Director Marketing | Reveal Email/Phone |
8 | Director Operations | Reveal Email/Phone |
9 | Enterprise Account Executive | Reveal Email/Phone |
10 | Sr. Partner B2C & Brands | Reveal Email/Phone |
Alembic Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11M | 76 | -7% | N/A | N/A |
What Is Alembic?
Alembic is a stealth phase startup that is developing cutting edge new technology.
keywords:N/AN/A
Total Funding
34
Number of Employees
$3.9M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alembic News
2022-04-20 - Alembic gets USFDA nod to market generic drug - Jammu ...
Alembic Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market lvabradine tablets, used to treat...
2022-04-20 - Alembic gets USFDA nod to market generic drug
Alembic said it has now received a cumulative total of 164 ANDA approvals (140 final approvals and 24 tentative approvals) from the USFDA...
2022-04-20 - Alembic Gets USFDA Nod To Market Ivabradine Used In ...
Alembic said it has now received a cumulative total of 164 ANDA approvals (140 final approvals and 24 tentative approvals) from the USFDA...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.6M | 34 | -19% | $14.2M |
#2 | $3.6M | 34 | 17% | $44M |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $3.6M | 34 | 0% | $11.4M |
#5 | $3.8M | 34 | N/A | N/A |